AWARD assessment of weekly administration of LY2189265 in diabetes (dulaglutide, 0.75 mg or 1.5 mg QW), BS bariatric surgery, BMI body mass index, DURATION diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), EQW exenatide QW, FM fat mass, GETGOAL GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, 20 g once daily), GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated haemoglobin, HD haemodialysis, LEAD liraglutide effect and action in diabetes (liraglutide 1.2 mg or 1.8 mg daily), OAD oral antidiabetics, RCT randomised controlled trial, SCALE satiety and clinical adiposityliraglutide evidence in individuals with and without diabetes, SGLT2 sodium-glucose co-transporter-2, SMM skeletal muscle mass, SUSTAIN-6 trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (semaglutide, 0.5 mg or 1.0 mg QW), T2DM type 2 diabetes mellitus, WMD weighted mean difference Cardiovascular Health GLP-1 RAs have been reported to be beneficial for cardiovascular health in patients with T2DM as these drugs aid in controlling cardiovascular (CV) risk factors such as hyperglycaemia, dyslipidaemia, weight gain and arterial hypertension (Tables 14, 15)
However, the price differential is usually modest, often ranging from $10 to $30 per vial depending on the pharmacy
[9] Bellini, A., Nicol, A., Bazzucchi, I., & Sacchetti, M
Among Americans with no personal or close connection to the medication, support drops to 55%
